Segall Bryant & Hamill LLC Trims Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX

Segall Bryant & Hamill LLC lowered its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 29.1% during the 1st quarter, HoldingsChannel reports. The fund owned 277,802 shares of the company’s stock after selling 113,969 shares during the period. Segall Bryant & Hamill LLC’s holdings in Amneal Pharmaceuticals were worth $3,453,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. Kemnay Advisory Services Inc. purchased a new position in shares of Amneal Pharmaceuticals in the fourth quarter valued at $26,000. Federated Hermes Inc. lifted its holdings in Amneal Pharmaceuticals by 1,680.6% during the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares in the last quarter. Comerica Bank boosted its stake in Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares during the period. Transamerica Financial Advisors LLC boosted its stake in Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after purchasing an additional 2,460 shares during the period. Finally, Focus Partners Wealth purchased a new position in Amneal Pharmaceuticals during the 3rd quarter valued at about $42,000. 31.82% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the transaction, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. The trade was a 27.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 17.30% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $18.85 on Tuesday. The company has a market cap of $6.01 billion, a PE ratio of 38.47 and a beta of 1.27. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65. The stock has a 50-day moving average price of $16.36 and a 200-day moving average price of $14.31. Amneal Pharmaceuticals, Inc. has a 12-month low of $7.80 and a 12-month high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The company had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. As a group, equities analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. UBS Group upped their price target on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Monday. The Goldman Sachs Group restated a “buy” rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a research report on Friday. Barclays boosted their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Finally, Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, July 29th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Amneal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $17.67.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.